, Projection de l'incidence et de la mortalité en France métropolitaine en 2017 -Rapport technique -Ref : RAINCMETRO17 [Internet, La famille des protéines Poly Adenoside diphosphate-Ribose Polymérase (PARP) est directement impliquée dans la stabilité du génome, la réparation de l'ADN et l'apoptose des cellules par Bibliographie 1. INCa, SFD. Recommandations Traitements des patients atteints de mélanome stade III inopérable ou e stade IV, 2017.
Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study, Eur J Cancer, vol.51, issue.15, pp.2179-90, 2015. ,
The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031, J Invest Dermatol, vol.136, issue.6, pp.1161-71, 2016. ,
The many unanswered questions related to the German skin cancer screening programme, Eur J Cancer, vol.64, pp.83-91, 2016. ,
DOI : 10.1016/j.ejca.2016.05.029
URL : https://hal.archives-ouvertes.fr/hal-01597297
Dermatologist-level classification of skin cancer with deep neural networks, Nature, vol.02, issue.7639, pp.115-123, 2017. ,
DOI : 10.1038/nature21056
Results of the 2016 International Skin Imaging Collaboration International Symposium on Biomedical Imaging challenge: Comparison of the accuracy of computer algorithms to dermatologists for the diagnosis of melanoma from dermoscopic images, J Am Acad Dermatol, vol.78, issue.2, pp.270-277, 2018. ,
Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists, Ann Oncol. 1 août, vol.29, issue.8, pp.1836-1878, 2018. ,
What's new in oncodermatology? ,
, Ann Dermatol Venereol. déc, vol.144, issue.4, pp.40-46, 2017.
Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study, BMJ. 28 juin, vol.357, p.2813, 2017. ,
Update to the recommendations for management of melanoma stages I to III ,
URL : https://hal.archives-ouvertes.fr/hal-01828764
, Ann Dermatol Venereol, vol.143, issue.10, pp.629-52, 2016.
, Société francaise de dermatologie, institut national du cancer. Recommandations mélanome métastatique rapport intégral, 2013.
Gaining momentum: New options and opportunities for the treatment of advanced melanoma, Cancer Treatment Reviews. sept, vol.41, issue.8, pp.660-70, 2015. ,
, Guide affection longue durée. Tumeur maligne, affection maligne tu tissu lymphatique ou hématopoïétique, Mélanome cutané, HAS, 2012.
Recommendations for genetic testing and management of individuals genetically at-risk of cutaneous melanoma ,
, Ann Dermatol Venereol. janv, vol.142, issue.1, pp.26-36, 2015.
High nevus counts confer a favorable prognosis in melanoma patients, Int J Cancer, vol.137, issue.7, pp.1691-1699, 2015. ,
History of Keratinocyte Carcinoma and Risk of Melanoma: A Prospective Cohort Study, J Natl Cancer Inst, vol.01, issue.4, 2017. ,
The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation, Br J Cancer. 14 févr, vol.116, issue.4, pp.536-545, 2017. ,
Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis, J Am Acad Dermatol. sept, vol.77, issue.3, pp.480-488, 2017. ,
Methotrexate treatment and risk for cutaneous malignant melanoma: a retrospective comparative registry-based cohort study, Br J Dermatol. juin, vol.176, issue.6, pp.1492-1501, 2017. ,
Dietary polychlorinated biphenyls, long-chain n-3 polyunsaturated fatty acids and incidence of malignant melanoma, Eur J Cancer, vol.72, pp.137-180, 2017. ,
Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?, J Invest Dermatol. mai, vol.134, issue.5, pp.1468-70, 2014. ,
Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression, Br J Cancer. 1 févr, vol.104, issue.3, pp.464-472, 2011. ,
Intra-and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma, PLoS ONE, vol.7, issue.1, p.29336, 2012. ,
SECOMBIT (sequential combo immuno and target therapy study): A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with metastatic melanoma and BRAF mutation, JCO. 20 mai, vol.35, pp.9598-9598, 2017. ,
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017, Eur J Cancer, vol.83, pp.247-57, 2017. ,
Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med. 11 juill, vol.369, issue.2, pp.122-155, 2013. ,
First oncolytic virus approved for melanoma immunotherapy, Oncoimmunology, vol.5, issue.1, p.1115641, 2016. ,
Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med. 19 août, vol.363, issue.8, pp.711-734, 2010. ,
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med. 30 juin, vol.364, issue.26, pp.2517-2543, 2011. ,
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med. 28 juin, vol.366, issue.26, pp.2443-54, 2012. ,
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J Clin Oncol. 1 avr, vol.32, issue.10, pp.1020-1050, 2014. ,
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Lancet Oncol. avr, vol.16, issue.4, pp.375-84, 2015. ,
Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med. 22 janv, vol.372, issue.4, pp.320-350, 2015. ,
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med. 11 juill, vol.369, issue.2, pp.134-178, 2013. ,
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol. août, vol.16, issue.8, pp.908-926, 2015. ,
Pembrolizumab versus Ipilimumab in Advanced Melanoma, N Engl J Med. 25 juin, vol.372, issue.26, pp.2521-2553, 2015. ,
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), Lancet, vol.390, pp.1853-62, 2017. ,
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N Engl J Med. 21 mai, vol.372, issue.21, pp.2006-2023, 2015. ,
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, N Engl J Med. 2 juill, vol.373, issue.1, pp.23-34, 2015. ,
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, N Engl J Med. 05, vol.377, issue.14, pp.1345-56, 2017. ,
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis, J Clin Oncol. 10 janv, vol.35, issue.2, pp.226-261, 2017. ,
Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose, Radiology. juin, vol.195, issue.3, pp.705-714, 1995. ,
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab, J Clin Oncol, vol.01, issue.13, pp.1510-1517, 2016. ,
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, Lancet Oncol. mai, vol.16, issue.5, pp.522-552, 2015. ,
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma, N Engl J Med, vol.09, pp.1824-1859, 2017. ,
Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma, Expert Rev Anticancer Ther, vol.10, issue.11, pp.1697-701, 2010. ,
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. 1 juill, vol.28, issue.suppl_4, pp.119-161, 2017. ,
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, Lancet Oncol, vol.18, issue.5, pp.611-633, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01807340
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions, Cancer Treat Rev. juin, vol.57, pp.36-49, 2017. ,
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials, J Clin Oncol. 1 déc, vol.35, issue.34, pp.3807-3821, 2017. ,
Radiation effects on antitumor immune responses: current perspectives and challenges, Ther Adv Med Oncol, vol.10, p.1758834017742575, 2018. ,
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy, Lancet Oncol, vol.16, issue.13, pp.498-509, 2015. ,
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy, OncoImmunology. 1 mai, vol.3, issue.5, p.28780, 2014. ,
Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy, Adv Radiat Oncol. sept, vol.3, issue.3, pp.399-404, 2018. ,
Brain metastases: epidemiology and pathophysiology, Cancer Treat Res, vol.136, pp.1-21, 2007. ,
Outcome variation among « radioresistant » brain metastases treated with stereotactic radiosurgery, Neurosurgery. mai, vol.56, issue.5, pp.936-945, 2005. ,
,
, Cancer Radiother. févr, vol.19, issue.1, pp.66-71, 2015.
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032, Radiother Oncol. mars, vol.98, issue.3, pp.394-403, 2011. ,
Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology, J Cancer Res Clin Oncol. janv, vol.140, issue.1, pp.151-158, 2014. ,
Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma, Am J Clin Oncol. déc, vol.34, issue.6, pp.603-613, 2011. ,
Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma, J Neurosurg. janv, vol.88, issue.1, pp.11-20, 1998. ,
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial, Lancet Oncol, vol.18, issue.8, pp.1049-60, 2017. ,
Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397), J Clin Oncol. 1 déc, vol.23, issue.34, pp.8870-8876, 2005. ,
A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores, Int J Radiat Oncol Biol Phys, vol.01, issue.1, pp.31-40, 2017. ,
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial, Lancet Oncol. mai, vol.13, issue.5, pp.459-65, 2012. ,
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial, Lancet Oncol. juill, vol.17, issue.7, pp.976-83, 2016. ,
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study, Lancet Oncol. mai, vol.19, issue.5, pp.672-81, 2018. ,
Ipilimumab and radiation therapy for melanoma brain metastases, Cancer Med. déc, vol.2, issue.6, pp.899-906, 2013. ,
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial, Lancet Oncol, vol.10, issue.11, pp.1037-1081, 2009. ,
Late radiation toxicity after whole brain radiotherapy: the influence of antiepileptic drugs, Am J Clin Oncol. déc, vol.22, issue.6, pp.573-582, 1999. ,
Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone, Int J Radiat Oncol Biol Phys. 1 août, vol.68, issue.5, pp.1388-95, 2007. ,
DOI : 10.1016/j.ijrobp.2007.03.048
URL : https://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/30164/1/IJROBP68-5.pdf
Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects, J Neurosurg. 5 janv, pp.1-10, 2018. ,
DOI : 10.3171/2017.7.jns171286
Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab, Oncoimmunology, vol.6, issue.3, p.1283461, 2017. ,
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery, Melanoma Res. juin, vol.23, issue.3, pp.191-196, 2013. ,
DOI : 10.1097/cmr.0b013e32835f3d90
Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control, Radiother Oncol, vol.125, issue.1, pp.80-88, 2017. ,
Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies, Eur J Cancer, vol.75, pp.169-78, 2017. ,
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases, Br J Cancer. 6 juin, vol.116, issue.12, pp.1558-63, 2017. ,
Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy, Ann Oncol. mars, vol.27, issue.3, pp.434-475, 2016. ,
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment, J Immunother Cancer, vol.17, issue.1, p.76, 2017. ,
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, vol.67, issue.6, pp.472-92, 2017. ,
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases, J Clin Oncol. 1 févr, vol.30, issue.4, pp.419-444, 2012. ,
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma, J Clin Oncol. 1 déc, vol.31, issue.34, pp.4311-4319, 2013. ,
,
, Ann Pathol. févr, vol.37, issue.1, pp.55-60, 2017.
Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases, Am J Clin Oncol, vol.40, issue.5, pp.444-50, 2017. ,
DOI : 10.1097/coc.0000000000000199
Metastatic melanoma: prognostic factors and survival in patients with brain metastases, J Neurooncol. déc, vol.135, issue.3, pp.507-519, 2017. ,
Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-oncology, vol.01, pp.162-74, 2017. ,
Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region, Human Pathology. 1 juill, vol.36, issue.7, pp.724-755, 2005. ,
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression, Clin Cancer Res. 15 juill, vol.23, issue.14, pp.3711-3731, 2017. ,
DOI : 10.1158/1078-0432.ccr-16-3215
URL : http://clincancerres.aacrjournals.org/content/clincanres/23/14/3711.full.pdf
, Common Terminology Criteria for Adverse Events (CTCAE), p.155, 2017.
Comparaison de quatre critères d'évaluation de la réponse tumorale chez les patients suivis pour un mélanome métastatique traités par anti-PD1, p.68 ,